Treatment and outcome of COVID-19 patients in a specialized hospital during the third wave: advance of age and increased mortality compared with the first/second waves
Tóm tắt
To elucidate the clinical course of patients with coronavirus disease 2019 (COVID-19) treated at a specialized hospital mainly for those with mild and moderate severity during the third wave, and to compare that with the first and second (1st/2nd) waves.
We retrospectively reviewed the severity on admission, treatment, and outcome of a total of 581 patients from September, 2020, to March, 2021, and examined the risk factors for deterioration of respiratory condition, defined as requiring oxygen ≥ 7 L/min for 12 h.
The median age was 78 (interquartile range 62−83) years, older than in the 1st/2nd waves (53 years), and 50% of the patients was male. The number of patients classified as mild (peripheral oxygen saturation (SpO2) ≥ 96%), moderate I, II, and severe (requiring admission to the ICU or mechanical ventilation) was 121, 324, 132, and 4, respectively. Favipiravir, ciclesonide, dexamethasone, and/or heparin were administered for treatment. Respiratory condition recovered in 496 (85%) patients. It worsened in 81 patients (14%); 51 (9%) of whom were transferred to tertiary hospitals and 30 (5%) died. Mortality rate increased by fivefold compared during the 1st/2nd waves. Age, male sex, increased body mass index, and C-reactive protein (CRP) on admission were responsible for worsening of the respiratory condition.
Patients were older in the third wave compared with the 1st/2nd waves. Respiratory condition recovered in 85%; whereas 5% of the patients died. Old age, male sex, increased body mass index, and CRP would be responsible for worsening of the respiratory condition.
Từ khóa
Tài liệu tham khảo
World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/. Accessed November 25, 2021
Matsui K, Inoue Y, Yamamoto K. Rethinking the current older-people-first policy for COVID-19 vaccination in Japan. J Epidemiol. 2021;31:518–9.
Oda Y, Shiraishi S, Shimada M, et al. Clinical profiles and outcome of patients with COVID-19 in a specialized hospital in Japan. J Anesth. 2021;35:405–11.
Ministry of Health, Labour and Welfare. Situation report. https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou_00006. html. Accessed November 25, 2021
Tanaka H, Hirayama A, Nagai H, et al. Increased transmissibility of the SARS-CoV-2 alpha variant in a Japanese population. Int J Environ Res Public Health. 2018;18:7752.
Karako K, Song P, Chen Y, et al. Overview of the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021. Biosci Trends. 2021;15:1–8.
Suehiro K. Preoperative assessment for scheduling surgery during the coronavirus disease pandemic. J Anesth. 2021;35:378–83.
Fujishiro A, Saito T, Asai T. COVID-19: be aware of contaminated airway devices. J Anesth. 2020;34:960–1.
Osaka Prefectural Goverment. About outbreak situation of new coronavirus infection patient. https://www.pref.osaka.lg.jp.e.agb. hp.transer.com/iryo/osakakansensho/happyo.html. Accessed November 25, 2021
Ito J, Seo R, Kawakami D, et al. Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: a single-center, retrospective, observational study. J Anesth. 2021;35:213–21.
Hattori T, Saito A, Chiba H, et al. Characteristics of COVID-19 patients admitted into two hospitals in Sapporo, Japan: analyses and insights from two outbreak waves. Respir Investig. 2021;59:180–6.
Clinical management of patients with COVID-19: a guide for front-line healthcare workers. version 2.1. https://www.niph.go.jp/h-crisis/wp-content/uploads/2020/07/20200706103735_content_000646531.pdf. Accessed November 25, 2021
National Center for Global Health and Medicine. Report of a multicenter, open-label, randomized phase II study to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 (RACCO study). https://www.ncgm.go.jp/pressrelease/2020/20201223_1.html. Accessed November 25, 2021
Osaka Institute of Public Health. Reports of confirmed COVID-19 patients in Osaka. http://www.iph.pref.osaka.jp/infection/disease/ corona.html. Accessed November 25, 2021
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11:e047007.
Mulder E, Pernett F, Schagatay E. A more holistic view could contribute to our understanding of ‘silent hypoxaemia’ in COVID-19 patients. J Physiol. 2021;599:3627–8.
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.
Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397:1646–57.
Our World in Data. Coronavirus (COVID-19) vaccinations. https://ourworldindata.org/covid-vaccinations. Accessed November 25, 2021